Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
May 17 2022 - 04:30PM
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that company management will present at the upcoming H.C. Wainwright Global Life Sciences Conference. A pre-recorded presentation will become available to registered conference attendees on May 24, 2022 at 7:00 a.m. ET. Management will discuss 2022 catalysts and potential milestones including the U.S. launch opportunity for omidubicel upon potential U.S. Food and Drug Administration approval, accelerating the development of its first-in-class NAM-enabled natural killer (NK) cell therapy candidate, GDA-201, as a potential new approach for patients with follicular and diffuse large B-cell lymphomas, and expansion of its NAM-enabled cell therapy pipeline with multiple next-generation, genetically engineered NK cells.
A webcast of the presentation will be available on the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.